Balancing two key proteins to enhance cancer treatment
Shifting the balance between IFN-I and TGF-beta to improve cancer therapy
This study is looking at how two proteins, TGFβ and IFNβ, work together in Triple Negative Breast Cancer to see if boosting IFNβ can help the immune system fight the cancer better and make treatments more effective for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10910029 on NIH RePORTER |
What this research studies
This research investigates how two proteins, Transforming Growth Factor β (TGFβ) and Interferon β (IFNβ), interact in the tumor microenvironment of Triple Negative Breast Cancer (TNBC). The study aims to understand how these proteins influence cancer cell behavior and the immune response, particularly focusing on how TGFβ can suppress the beneficial effects of IFNβ. By restoring IFNβ signaling, the research seeks to improve anti-tumor immunity and reduce cancer aggressiveness. Patients may benefit from new therapeutic strategies that target these pathways to enhance treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Triple Negative Breast Cancer who are facing challenges with treatment resistance.
Not a fit: Patients with non-aggressive forms of breast cancer or those not diagnosed with Triple Negative Breast Cancer may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies for patients with aggressive forms of breast cancer, potentially reducing metastasis and recurrence.
How similar studies have performed: Previous research has shown promising results in manipulating cytokine signaling pathways to improve cancer treatment outcomes, indicating that this approach may be viable.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Jackson, Mark W. — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Jackson, Mark W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.